- Baker Brothers’ 13F portfolio value increased from $11.54B to $11.80B.
- BeiGene stake was increased during the quarter.
- The top-three positions are Incyte Corporation, Seattle Genetics, and BeiGene and they add up to almost ~55% of the portfolio.
This article is part of a series that provides an ongoing
analysis of the changes made to Baker Brothers’ 13F portfolio on a quarterly
basis. It is based on Baker Brothers’ regulatory 13F Form filed on 05/14/2018.
This quarter, Baker Brothers’ 13F portfolio increased ~2%
from $11.54B to $11.80B. The top three holdings are at ~55% while the top five
holdings are close to ~68% of the 13F assets: Incyte Corporation (INCY),
Seattle Genetics (SGEN), BeiGene (BGNE), Alexion Pharmaceuticals (ALXN), and
BioMarin Pharmaceuticals (BMRN).
The spreadsheet below highlights changes to Baker Brothers’
13F holdings in Q1 2018. For a look at how the portfolio has progressed, please
see our previous
update:
To learn more about how to profit from a strategy of
following the best hedge fund picks, check out our book Profiting from Hedge Funds: Winning Strategies for the Little
Guy .
No comments :
Post a Comment